{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T18:13:34Z","timestamp":1778004814504,"version":"3.51.4"},"reference-count":39,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Concerns about the safety and efficacy of\n            <jats:italic>Mycobacterium bovis<\/jats:italic>\n            bacillus Calmette-Gue\u0301rin (BCG) emphasize the need for alternative tuberculosis (TB) vaccines. DNA vaccines are interesting candidates but are limited by the restricted antigen repertoire that they express. Traditional polycistronic vectors are large and have imbalanced expression. Recent advances in molecular genetics and cellular immunology have paved the way toward the rational design of an efficacious vaccine. We exploited self-cleaving peptide 2A from the foot-and-mouth disease virus, because of its small size and high cleavage activity, to generate an efficient TB DNA vaccine (V-2A). V-2A expresses three mycobacterial antigens, Rv3407, Ag85A, and HspX, in a single open reading frame joined by the 2A sequences, which lead to the segmentation of the long translated polypeptide into individual proteins by posttranslational modification. Our in vitro measurements revealed no differences at the transcriptional or translational level between V-2A and the monocistronic expression of the individual antigens. Mice vaccinated with V-2A developed antigen-specific cellular and humoral responses against all three antigens, imparting protection against\n            <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n            aerosol challenge equivalent to that imparted by BCG. These results have important implications for the rational design and development of efficacious recombinant subunit vaccines.\n          <\/jats:p>","DOI":"10.1128\/cvi.00237-09","type":"journal-article","created":{"date-parts":[[2009,8,6]],"date-time":"2009-08-06T01:10:51Z","timestamp":1249521051000},"page":"1467-1475","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":27,"title":["A Multicistronic DNA Vaccine Induces Significant Protection against Tuberculosis in Mice and Offers Flexibility in the Expressed Antigen Repertoire"],"prefix":"10.1128","volume":"16","author":[{"given":"Fayaz-Ahmad","family":"Mir","sequence":"first","affiliation":[{"name":"Max Planck Institute for Infection Biology, Department of Immunology, Charite\u0301platz 1, Berlin 10117, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan H. E.","family":"Kaufmann","sequence":"additional","affiliation":[{"name":"Max Planck Institute for Infection Biology, Department of Immunology, Charite\u0301platz 1, Berlin 10117, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Nasser","family":"Eddine","sequence":"additional","affiliation":[{"name":"Max Planck Institute for Infection Biology, Department of Immunology, Charite\u0301platz 1, Berlin 10117, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.62.6.2536-2544.1994"},{"key":"e_1_3_2_3_2","unstructured":"WHO report 2008: global tuberculosis control\u2014surveillance planning financing 2008"},{"key":"e_1_3_2_4_2","unstructured":"World Health Organization TB facts and figures 24 March 2005 2005"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.6.2951-2959.1998"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jama.1994.03510330076038","volume":"271","year":"1994","unstructured":"Colditz, G. A., T. F. Brewer, C. S. Berkey, M. E. Wilson, E. Burdick, H. V. Fineberg, and F. Mosteller. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA271:698-702.","journal-title":"JAMA"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1592"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.4.1527-1533.1998"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00063198-200205000-00006","volume":"8","year":"2002","unstructured":"Doherty, T. M., and P. Andersen. 2002. Tuberculosis vaccine development. Curr. Opin. Pulm. Med.8:183-187.","journal-title":"Curr. Opin. Pulm. Med."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0928-8244(98)00130-8","volume":"23","year":"1999","unstructured":"Ehlers, S. 1999. Immunity to tuberculosis: a delicate balance between protection and pathology. FEMS Immunol. Med. Microbiol.23:149-158.","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nbt1087","volume":"23","year":"2005","unstructured":"Fang, J., J. J. Qian, S. Yi, T. C. Harding, G. H. Tu, M. VanRoey, and K. Jooss. 2005. Stable antibody expression at therapeutic levels using the 2A peptide. Nat. Biotechnol.23:584-590.","journal-title":"Nat. Biotechnol."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92348-9"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.tube.2003.08.010","volume":"84","year":"2004","unstructured":"Flynn, J. L. 2004. Immunology of tuberculosis and implications in vaccine development. Tuberculosis84:93-101.","journal-title":"Tuberculosis"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1172\/JCI200419762","volume":"113","year":"2004","unstructured":"Furumoto, K., L. Soares, E. G. Engleman, and M. Merad. 2004. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J. Clin. Investig.113:774-783.","journal-title":"J. Clin. Investig."},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1016\/j.micinf.2006.04.025","volume":"8","year":"2006","unstructured":"Grover, A., M. F. Ahmed, B. Singh, I. Verma, P. Sharma, and G. K. Khuller. 2006. A multivalent combination of experimental antituberculosis DNA vaccines based on Ag85B and regions of difference antigens. Microbes Infect.8:2390-2399.","journal-title":"Microbes Infect."},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.vaccine.2006.07.020","volume":"25","year":"2007","unstructured":"Hesseling, A. C., B. J. Marais, R. P. Gie, H. S. Schaaf, P. E. Fine, P. Godfrey-Faussett, and N. Beyers. 2007. The risk of disseminated bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine25:14-18.","journal-title":"Vaccine"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(08)61036-3","volume":"372","year":"2008","unstructured":"Hoft, D. F. 2008. Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet372:164-175.","journal-title":"Lancet"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1073\/pnas.92.5.1530","volume":"92","year":"1995","unstructured":"Horwitz, M. A., B. W. Lee, B. J. Dillon, and G. Harth. 1995. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA92:1530-1534.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nm0896-893","volume":"2","year":"1996","unstructured":"Huygen, K., J. Content, O. Denis, D. L. Montgomery, A. M. Yawman, R. R. Deck, C. M. DeWitt, I. M. Orme, S. Baldwin, C. D'Souza, A. Drowart, E. Lozes, P. Vandenbussche, J. P. Van Vooren, M. A. Liu, and J. B. Ulmer. 1996. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat. Med.2:893-898.","journal-title":"Nat. Med."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.67.4.1702-1707.1999"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/35095558"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/79631","volume":"6","year":"2000","unstructured":"Kaufmann, S. H. 2000. Is the development of a new tuberculosis vaccine possible? Nat. Med.6:955-960.","journal-title":"Nat. Med."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"6382","DOI":"10.4049\/jimmunol.168.12.6382","volume":"168","year":"2002","unstructured":"Kursar, M., K. Bonhagen, A. Kohler, T. Kamradt, S. H. Kaufmann, and H. W. Mittrucker. 2002. Organ-specific CD4+ T cell response during Listeria monocytogenes infection. J. Immunol.168:6382-6387.","journal-title":"J. Immunol."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/22326","volume":"400","year":"1999","unstructured":"Lowrie, D. B., R. E. Tascon, V. L. Bonato, V. M. Lima, L. H. Faccioli, E. Stavropoulos, M. J. Colston, R. G. Hewinson, K. Moelling, and C. L. Silva. 1999. Therapy of tuberculosis in mice by DNA vaccination. Nature400:269-271.","journal-title":"Nature"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1128"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"12434","DOI":"10.1073\/pnas.0703510104","volume":"104","year":"2007","unstructured":"Mittrucker, H. W., U. Steinhoff, A. Kohler, M. Krause, D. Lazar, P. Mex, D. Miekley, and S. H. Kaufmann. 2007. Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. Proc. Natl. Acad. Sci. USA104:12434-12439.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.11.6471-6479.2004"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.72.10.6148-6150.2004"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.4.1949-1956.2002"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00004-07"},{"key":"e_1_3_2_31_2","first-page":"502","volume":"85","year":"1995","unstructured":"Roberts, A. D., M. G. Sonnenberg, D. J. Ordway, S. K. Furney, P. J. Brennan, J. T. Belisle, and I. M. Orme. 1995. Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis. Immunology85:502-508.","journal-title":"Immunology"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1002\/1521-4141(200106)31:6<1944::AID-IMMU1944>3.0.CO;2-R","volume":"31","year":"2001","unstructured":"Rolph, M. S., B. Raupach, H. H. Kobernick, H. L. Collins, B. Perarnau, F. A. Lemonnier, and S. H. Kaufmann. 2001. MHC class Ia-restricted T cells partially account for beta2-microglobulin-dependent resistance to Mycobacterium tuberculosis. Eur. J. Immunol.31:1944-1949.","journal-title":"Eur. J. Immunol."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01137-06"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.12.7618"},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1517\/14712598.8.9.1255","volume":"8","year":"2008","unstructured":"Souza, P. R., C. R. Zarate-Blades, J. I. Hori, S. G. Ramos, D. S. Lima, T. Schneider, R. S. Rosada, L. G. Torre, M. H. Santana, I. T. Brandao, A. P. Masson, A. A. Coelho-Castelo, V. L. Bonato, F. C. Galetti, E. D. Goncalves, D. A. Botte, J. B. Machado, and C. L. Silva. 2008. Protective efficacy of different strategies employing Mycobacterium leprae heat-shock protein 65 against tuberculosis. Expert Opin. Biol. Ther.8:1255-1264.","journal-title":"Expert Opin. Biol. Ther."},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/nm0896-888","volume":"2","year":"1996","unstructured":"Tascon, R. E., M. J. Colston, S. Ragno, E. Stavropoulos, D. Gregory, and D. B. Lowrie. 1996. Vaccination against tuberculosis by DNA injection. Nat. Med.2:888-892.","journal-title":"Nat. Med."},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1046\/j.1440-1711.2002.01087.x","volume":"80","year":"2002","unstructured":"Triccas, J. A., L. Sun, U. Palendira, and W. J. Britton. 2002. Comparative affects of plasmid-encoded interleukin 12 and interleukin 18 on the protective efficacy of DNA vaccination against Mycobacterium tuberculosis. Immunol. Cell Biol.80:346-350.","journal-title":"Immunol. Cell Biol."},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00434-08"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.5.2773-2778.2001"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1016\/j.vaccine.2008.06.044","volume":"26","year":"2008","unstructured":"Xu, J., W. Xu, X. Chen, D. Zhao, and Y. Wang. 2008. Recombinant DNA vaccine of the early secreted antigen ESAT-6 by Mycobacterium tuberculosis and Flt3 ligand enhanced the cell-mediated immunity in mice. Vaccine26:4519-4525.","journal-title":"Vaccine"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00237-09","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00237-09","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T15:54:54Z","timestamp":1627574094000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00237-09"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1128\/CVI.00237-09"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00237-09","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10]]},"assertion":[{"value":"2009-06-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-07-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}